Intranasal Insulin Ameliorates Cerebral Hypometabolism, Neuronal Loss, and Astrogliosis in Streptozotocin-Induced Alzheimer’s Rat Model

Neurotoxicity Research

Volumn 33, Issue 4, 2018, Pages 716-724

  Chen, Yanxing ^a   Guo, Zhangyu ^a   Mao, Yan Fang ^b   Zheng, Tingting ^a   Zhang, Baorong ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Alzheimer s disease; Glucose metabolism; Intranasal insulin; Positron emission tomography; Streptozotocin

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLIAL FIBRILLARY ACIDIC PROTEIN; INSULIN; NEURON SPECIFIC NUCLEAR PROTEIN; ANTIDIABETIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; STREPTOZOCIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; BRAIN METABOLISM; CINGULATE GYRUS; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BRAIN LEVEL; ENTORHINAL CORTEX; EXPERIMENTAL NEUROLOGIC DISEASE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; NERVE CELL NECROSIS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT MODEL; STREPTOZOTOCIN INDUCED ALZHEIMER DISEASE; TREATMENT DURATION; ANIMAL; APOPTOSIS; BRAIN CORTEX; CHEMICALLY INDUCED; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG EFFECT; GLIOSIS; INTRANASAL DRUG ADMINISTRATION; METABOLISM; NERVE CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; SPRAGUE DAWLEY RAT;

ADMINISTRATION, INTRANASAL; ALZHEIMER DISEASE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CEREBRAL CORTEX; DISEASE MODELS, ANIMAL; FLUORODEOXYGLUCOSE F18; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOSIS; HYPOGLYCEMIC AGENTS; INSULIN; MAGNETIC RESONANCE IMAGING; MALE; NEURONS; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY; STREPTOZOCIN;

EID: 85029604801     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-017-9809-7     Document Type: Article

References (45)

1. Arnsten AF, Wang M (2016) Targeting prefrontal cortical systems for drug development: potential therapies for cognitive disorders. Annu Rev Pharmacol Toxicol 56:339–360
2. Bedse G, Di Domenico F, Serviddio G, Cassano T (2015) Aberrant insulin signaling in Alzheimer’s disease: current knowledge. Front Neurosci 9:204
3. Benedict C, Hallschmid M, Hatke A, Schultes B, Fehm HL, Born J, Kern W (2004) Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29(10):1326–1334
4. Besson FL, La Joie R, Doeuvre L, Gaubert M, Mezenge F, Egret S, Landeau B, Barre L, Abbas A, Ibazizene M, de La Sayette V, Desgranges B, Eustache F, Chetelat G (2015) Cognitive and brain profiles associated with current neuroimaging biomarkers of preclinical Alzheimer’s disease. J Neurosci: Official J Soc Neurosci 35(29):10402–10411
5. Calvo-Ochoa E, Hernandez-Ortega K, Ferrera P, Morimoto S, Arias C (2014) Short-term high-fat-and-fructose feeding produces insulin signaling alterations accompanied by neurite and synaptic reduction and astroglial activation in the rat hippocampus. J Cereb Blood Flow Metab: Off J Int Soc Cereb Blood Flow Metab 34(6):1001–1008
6. Chen Y, Liang Z, Blanchard J, Dai CL, Sun S, Lee MH, Grundke-Iqbal I, Iqbal K, Liu F, Gong CX (2013) A non-transgenic mouse model (icv-STZ mouse) of Alzheimer’s disease: similarities to and differences from the transgenic model (3xTg-AD mouse). Mol Neurobiol 47(2):711–725
7. Chen Y, Liang Z, Tian Z, Blanchard J, Dai CL, Chalbot S, Iqbal K, Liu F, Gong CX (2014a) Intracerebroventricular streptozotocin exacerbates Alzheimer-like changes of 3xTg-AD mice. Mol Neurobiol 49(1):547–562
8. Chen Y, Zhang J, Zhang B, Gong CX (2016) Targeting insulin signaling for the treatment of Alzheimer’s disease. Curr Top Med Chem 16(5):485–492
9. Chen Y, Zhao Y, Dai CL, Liang Z, Run X, Iqbal K, Liu F, Gong CX (2014b) Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Abeta level and microglia activation in the brains of 3xTg-AD mice. Exp Neurol 261:610–619
10. Claxton A, Baker LD, Hanson A, Trittschuh EH, Cholerton B, Morgan A, Callaghan M, Arbuckle M, Behl C, Craft S (2015) Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer’s disease dementia. J Alzheimer's Dis: JAD 44(3):897–906
11. Craft S, Baker LD, Montine TJ, Minoshima S, Watson GS, Claxton A, Arbuckle M, Callaghan M, Tsai E, Plymate SR, Green PS, Leverenz J, Cross D, Gerton B (2012) Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch Neurol 69(1):29–38
12. Deng Y, Li B, Liu Y, Iqbal K, Grundke-Iqbal I, Gong CX (2009) Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: implication for Alzheimer’s disease. Am J Pathol 175(5):2089–2098
13. Dhuria SV, Hanson LR, Frey WH 2nd (2010) Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 99(4):1654–1673
14. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, Schwaiger M, Kurz A (2003) Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 30(8):1104–1113
15. Fletcher LC, Burke KE, Caine PL, Rinne NL, Braniff CA, Davis HR, Miles KA, Packer C (2013) Diagnosing Alzheimer’s disease: are we any nearer to useful biomarker-based, non-invasive tests? GMS Health Technol Assessment 9:Doc01
16. Freiherr J, Hallschmid M, Frey WH 2nd, Brunner YF, Chapman CD, Holscher C, Craft S, De Felice FG, Benedict C (2013) Intranasal insulin as a treatment for Alzheimer’s disease: a review of basic research and clinical evidence. CNS drugs 27(7):505–514
17. Gao F, Guo Y, Zhang H, Wang S, Wang J, Wu JM, Chen Z, Ding MP (2009) Anterior thalamic nucleus stimulation modulates regional cerebral metabolism: an FDG-MicroPET study in rats. Neurobiol Dis 34(3):477–483
18. Gao F, Wang S, Guo Y, Wang J, Lou M, Wu J, Ding M, Tian M, Zhang H (2010) Protective effects of repetitive transcranial magnetic stimulation in a rat model of transient cerebral ischaemia: a microPET study. Eur J Nucl Med Mol Imaging 37(5):954–961
19. Grieb P (2015) Intracerebroventricular streptozotocin injections as a model of Alzheimer’s disease: in search of a relevant mechanism. Mol Neurobiol 53(3):1741–1752
20. Guo Y, Gao F, Wang S, Ding Y, Zhang H, Wang J, Ding MP (2009) In vivo mapping of temporospatial changes in glucose utilization in rat brain during epileptogenesis: an 18F-fluorodeoxyglucose-small animal positron emission tomography study. Neuroscience 162(4):972–979
21. Hanson LR, Frey WH 2nd (2008) Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC neuroscience 3(Suppl):S5
22. Heo JH, Lee SR, Lee ST, Lee KM, Oh JH, Jang DP, Chang KT, Cho ZH (2011) Spatial distribution of glucose hypometabolism induced by intracerebroventricular streptozotocin in monkeys. J Alzheimer's Dis: JAD 25(3):517–523
23. Herholz K, Carter SF, Jones M (2007) Positron emission tomography imaging in dementia. Br J radiol 80(Spec No2):S160–S167
24. Kalafatakis K, Zarros A (2014) Intracerebroventricular administration of streptozotocin as an experimental approach to Alzheimer’s disease. Int J neurosci 124(12):944–946
25. Kamat PK, Kalani A, Rai S, Tota SK, Kumar A, Ahmad AS (2015) Streptozotocin intracerebroventricular-induced neurotoxicity and brain insulin resistance: a therapeutic intervention for treatment of sporadic Alzheimer’s disease (sAD)-like pathology. Mol Neurobiol 53(7):4548–4562
26. Kato T, Inui Y, Nakamura A, Ito K (2016) Brain fluorodeoxyglucose (FDG) PET in dementia. Ageing Res Rev 30:73–84
27. Kumar A, Singh A, Ekavali (2015) A review on Alzheimer’s disease pathophysiology and its management: an update. Pharmacol Rep: PR 67(2):195–203
28. Lenzen S (2008) The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 51(2):216–226
29. Lu Y, Ren J, Cui S, Chen J, Huang Y, Tang C, Shan B, Nie B, Xinsheng L (2015) Cerebral glucose metabolism assessment in rat models of Alzheimer’s disease: an 18F-FDG-PET study. Am J Alzheimer's Dis Other Dement 31(4):333–340
30. Macdonald IR, DeBay DR, Reid GA, O’Leary TP, Jollymore CT, Mawko G, Burrell S, Martin E, Bowen CV, Brown RE, Darvesh S (2014) Early detection of cerebral glucose uptake changes in the 5XFAD mouse. Curr Alzheimer Res 11(5):450–460
31. Mao YF, Guo Z, Zheng T, Jiang Y, Yan Y, Yin X, Chen Y, Zhang B (2016) Intranasal insulin alleviates cognitive deficits and amyloid pathology in young adult APPswe/PS1dE9 mice. Aging Cell 15(5):893–902
32. Marks DR, Tucker K, Cavallin MA, Mast TG, Fadool DA (2009) Awake intranasal insulin delivery modifies protein complexes and alters memory, anxiety, and olfactory behaviors. J Neurosci: Off J Soc Neurosci 29(20):6734–6751
33. Mosconi L (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 32(4):486–510
34. Mrak RE, Griffin WS (2001) Interleukin-1, neuroinflammation, and Alzheimer’s disease. Neurobiol Aging 22(6):903–908
35. Poisnel G, Herard AS, Tannir E, Tayara N, Bourrin E, Volk A, Kober F, Delatour B, Delzescaux T, Debeir T, Rooney T, Benavides J, Hantraye P, Dhenain M (2012) Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer’s disease. Neurobiol Aging 33(9):1995–2005
36. Prickaerts J, Fahrig T, Blokland A (1999) Cognitive performance and biochemical markers in septum, hippocampus and striatum of rats after an i.c.v. injection of streptozotocin: a correlation analysis. Behav Brain Res 102(1–2):73–88
37. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH 2nd, Craft S (2008) Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults. J Alzheimer's Dis: JAD 13(3):323–331
38. Schiffer WK, Mirrione MM, Dewey SL (2007) Optimizing experimental protocols for quantitative behavioral imaging with 18F-FDG in rodents. J Nucl Med: Off Publ Soc Nucl Med 48(2):277–287
39. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME (2001) Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286(17):2120–2127
40. Simpson IA, Chundu KR, Davies-Hill T, Honer WG, Davies P (1994) Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer’s disease. Ann Neurol 35(5):546–551
41. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer’s disease—is this type 3 diabetes? J Alzheimer's Dis: JAD 7(1):63–80
42. Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong C, Vlassenko AG, Benzinger TL, Stoops EE, Vanderstichele HM, Brix B, Darby HD, Vandijck ML, Ladenson JH, Morris JC, Holtzman DM, Fagan AM (2015) Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol 72(9):1029–1042
43. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, Szoeke C, Macaulay SL, Martins R, Maruff P, Ames D, Rowe CC, Masters CL, Australian Imaging B, Lifestyle Research G (2013) Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer’s disease: a prospective cohort study. Lancet Neurol 12(4):357–367
44. Willette AA, Bendlin BB, Starks EJ, Birdsill AC, Johnson SC, Christian BT, Okonkwo OC, La Rue A, Hermann BP, Koscik RL, Jonaitis EM, Sager MA, Asthana S (2015) Association of insulin resistance with cerebral glucose uptake in late middle-aged adults at risk for Alzheimer disease. JAMA Neurol 72(9):1013–1020
45. Zhang L, Guo Y, Hu H, Wang J, Liu Z, Gao F (2015) FDG-PET and NeuN-GFAP immunohistochemistry of hippocampus at different phases of the pilocarpine model of temporal lobe epilepsy. Int J Med Sci 12(3):288–294